LungLifeAI

About Circulogene Theranostics

Founded in 2015 and headquartered in Birmingham, Alabama, Circulogene Theranostics is a commercial-stage diagnostics company focused on precision oncology. Its core technology is a proprietary liquid biopsy platform that combines next-generation sequencing (NGS) and PCR to detect DNA, RNA, MSI, and PD-L1 status from a blood draw, aiming to complement or circumvent invasive tissue biopsies. The company has served over 25,000 patients and recently expanded its offerings with a tissue-based CGP assay and an exclusive AI-powered blood test for lung nodule risk stratification, positioning it in the high-growth liquid biopsy and early cancer detection markets.

Therapeutic Areas